Olema Oncology to Present New Data on OP-1250 at 2021 San Antonio Breast Cancer Symposium

NEXT STORY
FINN Partners Expands its Omni-Channel Communications Capabilities with Addition of Pharmacy Podcast Network
PREV STORY
Affimed Announces 100% Objective Response Rate at Highest Dose in Phase 1-2 Study of Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13 for CD30-positive Lymphomas
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Landos Biopharma Announces FDA Clearance of IND Application for Omilancor for the Treatment of Eosinophilic Esophagitis

author_avatar
NASDAQ Market News

iBio Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Corporate Update

author_avatar
NASDAQ Market News

ACR Releases Gout Management Guideline with Emphasis on Treat-to-Target Strategy for Urate Lowering Therapy

author_avatar
NASDAQ Market News